Coherus Cuts Headcount by About 30% and Narrows Its Pipeline to One Cancer Combination
- Coherus said it will reduce headcount by about 30% to narrow its focus on a Loqtorzi-based combination in esophageal cancer.
- Alongside the third-quarter report it cut full-year Loqtorzi guidance and flagged going-concern language, with cash runway under 12 months.
- It is not the first such cut: the company shed a similar share of staff last year after selling its Neulasta biosimilar.
💡 Points Based on public reports
A second ~30% cut in two years, plus going-concern language, signals a company trading breadth for survival on a single PD-1 label that is stalling commercially. The esophageal combination becomes the whole thesis, so its next readout or partnering outcome is the real catalyst. Watch whether a partner or sale emerges before the runway forces a worse deal.
📰 Source · Fierce Biotech ↗ Coherus shrinks headcount 30% to narrow focus of cancer combo